Your browser doesn't support javascript.
loading
PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang, M; Lawrence, J B; Quon, D V; Ducore, J; Simpson, M L; Boggio, L N; Mitchell, I S; Yuan, G; Alexander, W A; Schved, J-F.
Afiliação
  • Wang M; Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, USA.
  • Lawrence JB; LFB USA Inc., Framingham, MA, USA.
  • Quon DV; Orthopaedic Hemophilia Treatment Center, Orthopaedic Institute for Children, Los Angeles, CA, USA.
  • Ducore J; University of California, Davis, Comprehensive Cancer Center, Hematology/Oncology Clinic, Sacramento, CA, USA.
  • Simpson ML; Rush University Medical Center, Chicago, IL, USA.
  • Boggio LN; Rush University Medical Center, Chicago, IL, USA.
  • Mitchell IS; GLOVAL, LLC, Broomfield, CO, USA.
  • Yuan G; LFB USA Inc., Framingham, MA, USA.
  • Alexander WA; HEMA Biologics, LLC, Louisville, KY, USA.
  • Schved JF; Département d'Hématologie Biologique, Hôpital Saint-Eloi, CHU Montpellier, Montpellier, France.
Haemophilia ; 23(6): 832-843, 2017 Nov.
Article em En | MEDLINE | ID: mdl-28776894

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article